Fiserv Reiterated at Outperform and 3 Reiterated Ratings Making Rounds
Stock upgrades and downgrades are a controversial part of Wall Street. Despite regulations, many banks and firms still have a positive bias toward current clients and companies desired as future clients. In addition, Wall Street analysts are straight-up biased to the buy side. The percentage of sell recommendations is normally below 15 percent!
Regardless, upgrades and downgrades move stocks in the short-term. They fall into our CHEAT SHEET framework category ‘C = Catalyst for a Stock’s Movement’. Here are catalysts you must know today:
Constellation Brands (NYSE:STZ): Stifel Nicolaus reiterated its rating of Buy for this company and changed its price target from $42 to $45.
Current Price $35.6301
Fiserv (NASDAQ:FISV): Oppenheimer reiterated its rating of Outperform for this company and changed its price target from $80 to $89.
Current Price $82.98
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.
Celldex Therapeutics (NASDAQ:CLDX): Cantor Fitzgerald reiterated its rating of Buy for this company and changed its price target from $9 to $13.
Current Price $7.63
Lam Research (NASDAQ:LRCX): Needham reiterated its rating of Hold for this company and changed its price target from $40 to $43.
Current Price $37.84
Don’t Miss: These 4 Companies Are Cashing In On Oscar Buzz.